Daha Hızlı COVID-19 Teşhisine Doğru Yeni Yol Altınla Kaplandı

A HOLD Ücretsiz Sürüm 3 | eTurboNews | eTN
Linda Hohnholz'un avatarı
Tarafından yazılmıştır Linda Hohnholz

Researchers used gold nanoparticles to develop a new molecular diagnostic platform that considerably reduces the time required for COVID-19 detection.

The rapid spread of COVID-19, a disease caused by the SARS-CoV-2 virus, has created a public health crisis around the world. Early COVID-19 detection and isolation are key for controlling disease transmission and protecting vulnerable populations. The current standard for COVID-19 diagnosis is reverse transcriptase-polymerase chain reaction (RT-PCR), a technique in which viral genes are detected after they undergo multiples cycles of amplification. However, this technique is time-consuming, creating a testing backlog across diagnostic centers and leading to delayed diagnoses.      

In a recent study published in Biosensors and Bioelectronics, researchers from Korea and China have introduced a novel nanotechnology-based platform that can shorten the time required for COVID-19 diagnosis. Their surface-enhanced Raman scattering (SERS)-PCR detection platform—prepared using gold nanoparticles (AuNPs) in the cavities of Au ‘nanodimple’ substrates (AuNDSs)—can detect viral genes after only 8 cycles of amplification. That is almost one-third of the number required with conventional RT-PCR.

“Conventional RT-PCR is based on the detection of fluorescence signals, so 3–4 hours are required to detect SARS-CoV-2. This speed is not enough considering how rapidly COVID-19 spreads. We wanted to find a way to cut this time at least by half,” says Prof. Jaebum Choo, explaining the motivation behind the study. Fortunately, the answer was not too far. In a previous study published in 2021, Prof. Choo’s team had developed a novel detection platform in which high-sensitivity SERS signals are produced by AuNPs uniformly arranged in the cavities of AuNDSs through a technique called DNA hybridization. Based on this previous discovery, Prof. Choo and his team developed the novel SERS-PCR platform for COVID-19 diagnosis.

The newly developed SERS-PCR assay uses SERS signals to detect “bridge DNA”—small DNA probes that slowly break down in the presence of target viral genes. Therefore, in samples from patients positive for COVID-19, the concentration of bridge DNA (and therefore the SERS signal) continuously decreases with progressive PCR cycles. In contrast, when SARS-CoV-2 is absent, the SERS signal remains unchanged.

The team tested the effectiveness of their system using two representative target markers of SARS-CoV-2, namely, the envelope protein (E) and RNA-dependent RNA polymerase (RdRp) genes of SARS-CoV-2. While 25 cycles were required for RT-PCR-based detection, the AuNDS-based SERS-PCR platform required only 8 cycles, considerably reducing the testing duration. “Although our results are preliminary, they provide an important proof-of-concept for the validity of SERS-PCR as a diagnostic technique. Our AuNDS-based SERS-PCR technique is a promising new molecular diagnostic platform that can considerably shorten the time required for gene detection compared to conventional RT-PCR techniques. This model can be further expanded by incorporating an automatic sampler to develop a next-generation molecular diagnostic system,” explains Prof. Choo.

Indeed, SERS-PCR could be an important tool in our arsenal against the COVID-19 pandemic. It could also create a paradigm shift in the field of molecular diagnostics, revolutionizing how we detect infectious diseases and tackle future epidemics.

Yazar hakkında

Linda Hohnholz'un avatarı

Linda Hohnholz

Genel Yayın Yönetmeni eTurboNews eTN HQ merkezli.

Üye olun
Bildirir
konuk
0 Yorumlar
Satır İçi Geri Bildirimler
Tüm yorumları görüntüle
0
Düşüncelerinizi ister misiniz, lütfen yorum yapın.x
()
x
Paylaş...